Tag Archives: nasdaq

DHS: Strong Dividend, Intelligent Holdings, Solid Sector Allocations

Summary The dividend yield is a strong 3.41%. The holdings include several established dividend champions which gives the portfolio a more durable feel. The sector allocations look respectably defensive which is a positive when I would consider the market to still be moderately expensive. The Federal Reserve pushing short rates higher could help the financial sector generate more interest income. The WisdomTree Equity Income ETF (NYSEARCA: DHS ) hits very well on 3 of 4 categories. The only weakness in this fund is the expense ratio. The dividend yield, holdings, and sector allocations create a very compelling trio of factors in favor of the ETF. Expenses The expense ratio is a .38%, which is fairly standard for several of the WisdomTree (NASDAQ: WETF ) funds I’ve looked into. Dividend Yield The dividend yield is currently running 3.41%. This is simply excellent, no complaints there. Holdings I grabbed the following chart to demonstrate the weight of the top 18 holdings: (click to enlarge) General Electric (NYSE: GE ) has had a disappointing several years as their strong dividend has not been matched with solid share price growth. However the company has been very active in looking for solutions and even took measures as extreme as turning one of their departments into Synchrony Financial (NYSE: SYF ). To be fair, it is unclear to me why the finance division that turned into Synchrony Financial was supposed to fit with the rest of the company at GE. Exxon Mobil (NYSE: XOM ) and Chevron Corp (NYSE: CVX ) both get heavy allocations and have huge dividends. Oil is extremely “out of favor” right now, but I expect an eventual comeback. If it never comes, at least the oil for my truck will be fairly cheap. Two of the highest holdings go to the telecommunications sector with AT&T (NYSE: T ) and Verizon (NYSE: VZ ). I’ve found those allocations to be fairly risky given the aggressive competition in the telecommunications industry, but there are some positive aspects to doing a heavy allocation here as it aligns part of the risk with the investor’s expenses. If T and VZ are having a hard time covering their dividend, it would indicate that the profits within the telecommunications industry had dried up and would suggest that the investor is probably saving a chunk of money on their cell phone bill each month. McDonald’s (NYSE: MCD ) is another holding that I think should be represented in most dividend growth portfolios in one way or another. While their burgers have left a great deal to be desired over the last few years, they have still been able to remain relevant because they collected a large amount of high quality real estate. Over the last earnings report things began to look materially better for this real estate giant disguised as a seller of cheap burgers. Phillip Morris (NYSE: PM ), Altria Group (NYSE: MO ), and Coke (NYSE: KO ) all sell products that kill people, but they continue to deliver sales and earnings and the earnings are used to pay some fairly attractive dividends. I know some investors might think I’m crazy for tossing Coke in there with the tobacco companies, but high fructose corn syrup has quite a few very damaging health effects and heart failure is a major source of death in the United States. You won’t see me protesting the stable dividend though. Sectors Financials get a heavy weight which might be a good thing with the Federal Reserve working so hard to raise rates and justify paying interest on excess reserves when the rest of the world is shifting towards further rounds of quantitative easing or NIRP (negative interest rate policy). We have learned over the last few years that negative nominal returns and negative real returns are very possible because simply holding onto cash creates other problems. It turns out that protecting cash is not free and that banks can be pushed to accept negative interest rate policies. That’s interesting and it suggests there will be quite a few books on macroeconomics that need to have chapters replaced. The heavy allocations to consumer staples and energy look good in my opinion since I like the defensive nature of the consumer staples sector and appreciate the energy exposure as demonstrated in my comments on XOM and CVX. The three defensive sectors are consumer staples, utilities, and health care. Those three are all present in the top 6 allocations, so this looks like a respectably defensive fund. Since P/E ratios are fairly across most of the market, I prefer a defensive portfolio to an aggressive portfolio. Conclusion Great dividend, mediocre expense ratio, great holdings, and great sector weightings make a fairly attractive portfolio. If the expense ratio were lower it would get some very serious consideration from me. This fund simply performs great on several metrics.

PSP Yields 8.00% And Outperforms The S&P, But What Are The Risks?

Summary This Global Listed Private Equity Portfolio is under the radar with little institutional ownership. With an easy to analyze portfolio of 64 holdings we are slightly surprised by the lack of “buzz”. We analyze this attractive performing ETF, notice a similarity with MLPs that outperform when rates rise, and provide our recommendation. The PowerShares Global Listed Private Equity Portfolio ETF (NYSEARCA: PSP ), is a well established fund, (inception 10/24/2006) with an attractive track record. It had a serious correction during the financial crises but has weathered the storm and come back significantly, similar to the holdings of the underlying components. The ETF is based upon an index called the Red Rocks Global Listed Private Equity Index. Red Rocks Capital is an asset management firm based in Golden, Colorado. Red Rocks specializes in listed private equity securities. They are owned by ALPS, a mutual fund and asset servicing and gathering firm based in Denver, Co. They are in turn a wholly owned subsidiary of DST Systems (NYSE: DST ), a software development firm based in Kansas City, Missouri. The ETF presently has 64 holdings while the index with a ticker symbol of {GLPEXUTR} has anywhere from 62-70 or an unknown number of holdings. We will explain why shortly. According to the sponsor PowerShares: The PowerShares Global Listed Private Equity Portfolio is based on the Red Rocks Global Listed Private Equity Index. The Fund will normally invest at least 90% of its total assets in securities, which may include American depository receipts and global depository receipts, that comprise the Index. The Index includes securities, ADRs and GDRs of 40 to 75 private equity companies, including business development companies BDCS, master limited partnerships MLPS and other vehicles whose principal business is to invest in, lend capital to or provide services to privately held companies (collectively, listed private equity companies). The Fund and the Index are rebalanced and reconstituted quarterly. The market cap and style allocations are interesting but not terribly relevant. For information purposes here are the allocations, courtesy of the fund sponsor, Invesco: PSP Market Cap & Style Allocations Classifications Weight Small-Cap = 27.49% Growth 2.44% Blend 3.28% Value 21.77% Mid-Cap = 56.70% Growth 27.60% Blend 16.78% Value 12.32% Large-Cap = 15.81% Growth 8.13% Blend 7.03% Value 0.65% There are no great surprises here as we expected that most of the constituents to this ETF would be solidly in a mid-cap structure. The general nature of most BDCs, MLPs and private equity firms for both tax and overall structure are neither extremely large, nor small. As a comparison, Morningstar breaks the allocation down slightly more: Micro-cap: 13.41%, Small-Cap: 14.08%, Medium-Cap: 56.70%, Large: 8.78%, and Giant: 7.03%. Obviously, they use a slightly different nomenclature and breakdown, but both Morningstar and the fund sponsor do concur exactly on the category of Medium or Mid-Cap. In terms of the style overall it is categorically a blend style with XTF.com breaking it down as follows: Blend, 81.10%, Growth, 9.50%, Value 6.50% and Pure Growth at 2.70% As this is a global fund, it is important to analyze the country and currency allocations of the holdings. PSP Country and Currency Allocations Country Weight Currency Weight United States 40.06% United States Dollar 40.06% United Kingdom 15.21% Euro 16.00% France 7.13% British Pound 15.21% Canada 6.02% Canadian Dollar 6.02% Switzerland 5.66% Swiss Franc 5.66% China 5.63% China Renminbi 5.63% South Africa 4.28% South Africa Rand 4.28% Belgium 3.95% NA NA Germany 3.28% NA NA Sweden 3.15% Swedish Krona 3.15% Japan 2.46% Japan Yen 2.46% Denmark 1.03% Danish Krone 1.03% Malta 1.64% NA NA Hong Kong 0.50% Hong Kong Dollar 0.50% As a global ETF this would be considered well balanced geographically with approximately 46.00% in North America and approximately 41% in the Europe. Geographically, the holdings shifted slightly from the last quarter, with a small percentage of assets moving to South Africa out of Malta. In terms of currency exposure, we don’t see the as a major influence on this ETF with the slight exception of weakness in China and continued weakness in the euro. In any event, the ETF is priced in dollars and the exposure, though unhedged, is fairly balanced. The U.S. dollar as the underlying currency at 40% and the other currencies make up an interesting mix overall. Any further concern is not directed at the currencies in this ETF, though it would be prudent of course to follow the euro based holdings and the small exposure to China. Our sector allocation of this ETF is related to the overall nature of private equity firms in general. For informational purposes here is the sector allocation: PSP Sector Allocations Sector Weight Financials 74.64% Derivatives 8.80% Industrials 8.27% Information Technology 4.89% Health Care 1.18% Investment Companies 1.11% Consumer Staples 1.03% Energy 0.08% The majority of the BDCs, MLPs, and private equity firms would be classified within the Financial Sector. Although a little difficult and subject to error, an analysis of the underlying industries is informative when we analyze a private equity firm and it components. In terms of PSP, it does shed light on the business nature of the holdings. PSP Industry Allocations Industry Exposure Weight Consumer Finance 59.70% Financial Services 22.70% Internet & Mobile Applications 4.70% Heavy Machinery 3.90% Steel 3.30% Other 2.20% Packaged Food Products 1.20% Health Care Providers & Services 0.90% Energy Equipment & Services 0.70% Investment Companies 0.60% This industry breakdown is courtesy of xtf.com and is subject to revision. As noted, many of the private equity, BDCs and MLPs within this ETF are focused on providing financing for other businesses and industries yet the underlying holdings can focus on specific industries as well. Investors who have never invested in these companies or analyzed these holdings may require a “learning curve” to understand how the firms are structured and the benefit of their overall tax structure. There is also history on their side, if and when, rates do increase. We will explain that shortly. Before doing so we will as usual analyze the top 15 components. For information purposes here are the top 15 components, their symbol, sector, ratings, (if any) and their weightings: PSP top 15 components Name/Symbol Sector Ratings (Moody’s/S&P) Weight Partners Group Holding AG ( OTCPK:PGPHF ) Financials NR/NR 5.661% 3i Group PLC ( OTCPK:TGOPY ) Financials NR/BBB 5.422% Onex Corp ( OTCPK:ONEXF ) Financials NR/NR 5.363% Fosun International Ltd ( OTCPK:FOSUY ) Industrials Ba3/BB 5.130% Citi KKR & Co, TRS 10/31/13/NA Derivatives NA/NA 4.505% Citi Blackstone TRS 10/31/13 Asset LG/NA Derivatives NA/NA 4.293% Eurazeo SA ( OTC:EUZOF ) Financials NR/NR 3.693% Brait SE/{BAT.J} Financials NR/NR 3.606% Leucadia National Corp (NYSE: LUK ) Financials Ba1/BBB- 3.287% Melrose Industries PLC ( OTC:MLSPY ) Industrials NR/NR 3.140% IAC/InterActive Corp (NASDAQ: IACI ) Information Technology Ba2/BB 2.981% Ares Capital Corp (NASDAQ: ARCC ) Financials Ba1/BBB 2.967% Ackermans & van Haaren NV ( OTCPK:AVHNY ) Financials NR/NR 2.924% Wendel SA ( OTCPK:WNDLF ) Financials NR/BBB- 2.914% Jafco Co Ltd ( OTC:JAFCY ) Financials NR/NR 2.461% Our top 15 holdings represent 58.347% of the ETF, while the balance of 49 holdings represent 41.653%. This is quite a top heavy ETF with 8.798%, (or 15.078% of the top 15) of the ETF in combined total return swaps that originated with Citi (NYSE: C ) and KKR (NYSE: KKR ) and Citi and Blackstone (NYSE: BX ). Basically, these swaps allow the ETF fund managers to utilize capital more effectively. A little tutorial on TRS is necessary. These swaps allow the ETF and its fund shareholders to receive a total return and gain exposure and benefit in the sector without actually having ownership. Income is also generated from the swap as well as appreciation of the asset over the life of the swap. A set rate is paid for the swap and if the asset does fall over the swap’s lifespan, the total return receiver or counterparty will be required to pay the asset owner the amount by which the asset has fallen in price. These Citi/KKR and Citi/Blackstone TRS are considered unrated derivative contracts. In terms of the company names, most of the names are only slightly “household names,” but fairly well known in professional investment circles. Many of the companies would be considered “holding companies,” due to their structures by ratings agencies in spite of the fact they would be classified as PE funds and BDCs. One of the top ten is Brait SE, whose name is derived from an uncut diamond. It is a Luxembourg and Johannesburg Exchange listed large South Africa based PE fund with no U.S. symbol whatsoever. Many of the companies in the index are listed on the “Pink sheets.” The primary reason is there are limited financial disclosures and reporting requirements. Yet the public vehicle is useful for both compensation plans and for retail participation in the sector, as long as proper risk disclosures occur. In our past analysis of ETFs we always provided the weighting of the index constituents. The purpose is to discern any discrepancies or variances in the current market between the index and the fund. This is also known of course by the term “tracking error.” Usually we can at least provide somewhat up to date information. BarCap, S&P, MS, and even small providers were more than happy to share their index composition with readers of Seeking Alpha. In this case, we were unsuccessful. One of the VP’s in Portfolio Strategy stated: I cannot provide any more information. There are some regulatory changes that are affecting how we report index information, so this has delayed the update of our fact sheet. There is an updated (9/30) fact sheet that is undergoing compliance review, but this may not be available for another 1-2 weeks. We are obviously slightly disheartened here. The only thing we can reference that pertains to what he is referring to was a new regulatory issue that pertains to shares in ETFs noted in a Reuters article and other investment publications. According to the article: ETFs are typically funds whose holdings are meant to mimic the performance of an index. To do that, the SEC has said the securities used to create shares in most funds must be the same ones as in the fund’s portfolio unless there was a change in the index the fund tracks. In any event, this seems more pertinent to Invesco than the index provider. We welcome SEC attorneys or fund practitioners to share further information. We felt his feedback was quite uncommon and obviously not transparent for an index provider. Overall, this is a little circumspect and disheartening. We like to inform the readers of any divergence or tracking errors from the index. In this case all we had to work with is data that “stale dated” from June information that basically shows the top ten holdings with no weightings whatsoever. Fortunately, the ETF fund information was up to date and an analysis for the top 15 holdings was possible. As noted, ratings on these issues are not prevalent and actually not pertinent. Only 14.59% from the top 15 or 25% have investment grade ratings. The reason is due to the structure of the firms in this ETF. Many of them do not have strong balance sheets. Some have substantial debt, including high yield paper. This does not endear or permit, in most cases an investment grade credit rating. In addition, many of these public firms see no need to apply for a rating as they basically borrow and lend and invest in the private markets using alternative sources of capital. In general, they have no use for credit ratings in their overall business model. By the way, the 16th holding is the well known Apollo global Management with 2.241%, and the Carlyle Group comes in at 22nd with 1.608% of the ETF. Overall, the benefit of the ETF holder is to participate in an alternative market that may be the place for stable cash flow and growth, if and when rates rise. We will explain this aspect shortly as we review the performance and key data of the ETF. PSP’s Performance, Fees and Recommendation Category PSP {ETF} GLPEXUTR {Index} Net Expense Ratio 2.09% NA Turnover Ratio 30.00% NA YTD Return 5.49% (10/31/15) 5.71% (10/31/15) 1-Year Total Return 6.42% (10/31/15) 7.97% (10/31/15) Distribution Yield/SEC Yield 8.04%/3.27%(11/18/15) 3.86%/NA (06/30/15) Beta,(3 year) Shares/Holdings (shares vs Morningstar Global Allocation TR USD) 1.66/1.1 NA/NA P/E Ratio FY1/current 13.93/12.65 (09/30/15) NA/NA Price/Book Ratio FY1/current 1.78/1.71 (09/30/15) NA/NA The fees here are basically standard in PE and BDCs ETFs. 1.45% of the 2.09% of the fees are the pro rated portion of the cumulative expenses that are charged by the underlying holdings. It is the usual large fees that are expected in this alternative sector. This is in spite of the fact that Fidelity uses a rather small number of 0.53% for the net expense ratio for the asset class median. The turnover ratio of 30% is also higher than the asset class median of 18.00%. We attribute this to changes in the ETF and the underlying index throughout the year. The YTD return is almost 2xs the S&P 500 return (2.65%) and exceeds the 12 month return as well (5.20%). The beta for the underlying is close to the benchmark and is attributed to the lack of volatility of the publicly traded shares and general long term nature of PE holdings. The biggest issue with this ETF is the distribution yield. The returns generated here are considered neither short term nor long term capital gains, but dividend income. If the PE funds in PSP, even though public listings, are structured as MLP’s (Master Limited Partnerships) this creates a tax issue. The funds themselves as a MLP have a tax incentive to distribute most nearly all their profits to their shareholders. This creates major tax issues for investors in MLPs. Fortunately, the majority of the firms in the ETF are structured under a holding company or owners of a MLP. This allows these profits to flow as dividend income and not as capital gains. We mentioned in the beginning why we are encouraged by market moves in these firms during a rate rise. Though the underlying companies are not, for the most part structured as MLPs they do tend to trade at times like them and investors due at times “bucket” them, BDC’s, and listed PE funds all together. This fund as we mentioned, only dates as to 2006, so we can not ascertain how it will do overall during a rate increase. We looked into the history of MLP’s and noticed an interesting article. Fortune Magazine’s, November 01, 2015, stated: They also find encouragement in recent history: The last time the Fed increased rates, between June 2004 and June 2006, the S&P MLP index rose 17%, beating the S&P 500’s 12% gain. Yes, we know this article is primarily on pipeline MLPs but does address MLPs in general. The main takeaway on this article is that the companies did not contract during an interest rate increase. It actually is logical. The underlying holdings are based upon companies that are either being restructured, turned around, purchased for resale, or merged with other entities. During periods of interest rate increases general aggregate demand increases. In general, the Fed Reserve and other central banks try to stay ahead of demand and inflation. Granted, this is a global PE ETF with 40.00% in the U.S., but in general the U.S. economy will globally lead the way forward. In the event of no interest rates due to a myriad of reasons, we expect this ETF to continue to perform and return an above market return to investors. Overall, we are extremely bullish on the sector and this ETF and recommend a buy as an alternative investment. We are encouraged by the growth of the underlying holdings within the fund constituents. It is one of the few vehicles in the market where both institutions and individuals can invest in a PE or BDC fund, albeit in an indirect way. The ETF closed at $10.88 per share on November 19. Its year high was $12.41, set on June 03 and its year low of $9.01 was on August 24. Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Exclusive Interview With Paul Yook, BioShares’ Portfolio Manager

Summary I interview Paul Yook, the portfolio manager of BioShares. We spoke about the BioShares Biotechnology Clinical Trials ETF (BBC). This ETF offers investors pure exposure to the biotech market without exposure to special pharmaceutical companies. After my article on iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) portfolio strategy, many readers have asked about other biotech ETFs that could act as replacements for IBB. Though my first reaction is to say ALPS Medical Breakthroughs ETF (NYSEARCA: SBIO ) because I was previously long on SBIO, I realized I don’t know much of the differences among the different biotech stocks. SBIO is often brought up when BioShares Biotechnology Clinical Trials ETF (NASDAQ: BBC ) is mentioned, but much of the information on BBC – and the differences between it and SBIO – seem to be elusive, at least online. So, I scheduled an interview with Paul Yook, the portfolio manager of BBC to ask him more about this little-known biotech ETF. The interview follows. Q : Because most drugs fail their clinical trials, many of the holdings in BioShares Biotechnology Clinical Trials ETF will likely fall, requiring the handful of winners to compensate for the losses. What is the likelihood of such compensation? PY : Great question. Let’s keep in mind that most publicly trading biotech companies have a number of shots on goals. Though the majority of products fail, most companies have follow-on products. So, companies have multiple compounds focusing on the same downstream target. And they’ll have multiple programs – different disease targets and drug candidates. So it doesn’t necessarily require the lead product or one individual product to make a successful drug. There are a number of successful publicly traded companies such as Regeneron (NASDAQ: REGN ) who had a number of failures in their early years but ended up being successful investments over time. So, when you ask the odds of successful investments in biotech, we believe that diversification through a variety of investments is important. It is really difficult to pick a single winning stock and stomaching the volatility that goes with investing in biotech. Having a diverse basket is really important in investing in clinical stage companies. Q : So basically, all of the holdings you have in BBC have multiple shots at success? PY : They do because – again every company is different – most publicly trading companies have a diverse pipeline. In addition, these management teams really are portfolio managers in a way. They are assessing the risk of these programs over time. And they can pivot: They can move into another program; they can acquire a program; they can change their scientific approach. You’re really investing in a management team, just as you are in an individual drug or portfolio of drugs. Q : If I’m not mistaken, BBC removes a company from their holdings if that company doesn’t currently have a drug in a clinical trial, correct? PY : Exactly right. BBC invests in companies with lead companies in phases I, II, and III. Q : What is your stance on the increasing failure rate of clinical trials? PY : As far as clinical trials over time, there is variability from year to year. Some of the scientific approaches we’ve seen have sped up the time it takes to get a drug approved, starting from inception or conception of the idea. There are other disease categories such as heart failure or stroke that have had very poor statistical results. We look at failure rate across category. We believe investing across these categories is the most prudent way to invest. Q : So you’re looking at the failure for each type of drug instead of simply clinical trials in general? PY : Exactly. Certain categories tend to be of lower risk. For example, if a company is developing an enzyme replacement therapy for a genetic disease, it will tend to have a very high success rate because the biology of such a therapy is well known. Q : In general, what are the criteria you use to pick your holdings? PY : Our criteria for our index funds are rules-based. They are really very simple. We first screen for biotech companies that are primarily focused on human therapeutic drugs. There are other companies that focus on other industries, such as specialty pharmaceuticals, diagnostics, or life science tools. We exclude these from our biotech funds because we believe biotech ETFs should give investors biotech-only exposure. We also screen companies that have a minimize size and liquidity: 250 million in market cap and $200 million of average traded volume. This way we exclude smaller companies that have problems with financing and capital. Of course, our main criterion is that the company being in the clinical trial stage. We split the universe up into the companies in that early stage, which go into BBC, from the later stage companies that go into the BBP fund. Q : Seeing as BBC is not actively managed, how much weight should investors give to the biotech specialists behind this ETF? PY : I have been involved in active management, and what I find in the investment universe today is that biotech investors have become very knowledgeable. What you have today is many scientists at large institutions such as hedge funds and mutual funds. You also have highly sophisticated retail individuals active on blogs and Twitter. I think the playing field has become much more equalized, and the market has become much more efficient for biotech investing. I think the differential between active and management has really narrowed. In many ways, I think there’s an edge to investing in passive strategies. What we’ve seen is what I call “alpha destruction” from active studies. There was a Bloomberg study in the summer that looked at a variety of healthcare and biotech hedge funds and mutual funds, finding them to underperform the passive ETF strategies. Of course, active strategies also have negative tax ramifications, lockup minimums, and liquidity issues. This has been widely written about. There are large advantages in passive, ETF strategies. I believe that passive strategies really help investors avoid some of the pitfalls of those active strategies. A lot of investors tend to sell out of fear, whereas passive strategies by rule avoid that pitfall. Q : Right. I think a lot of investors are looking for ETFs because of the lower management fees involved. BBC charges 0.85%. In addition, many investors don’t have the science background to make good choices in the biotech market, which is why it’s important for an ETF to employ specialists in index creation. So for BBC, what is the general background of your fund’s biotech specialists? PY : Keep in mind that we do have a passive strategy. I did lay out our rules, which are fairly simple. But it is important that we manage our own index. We employ 25 specialists, both biotech and industry specialists. We look for people with a passion in investing in biotech and currently have 6 Ph.D. level scientists. We have a wide variety of investment and capital market experience, from investment banks and equity research to hedge funds and mutual funds. The reason it’s important to have specialists creating our biotech indexes is because we employ a level of understanding in the creation of these indexes. Most indexes today date back to the 1990s. At that time, the biotech industry was in its infancy. It was unclear the direction the industry was heading. It was also unclear what the eventual profit model would be. Back then, we saw sub-industries like genomics and stem cell technologies that people didn’t really understand. Today, the industry is very different. There are many sub-segments of the biotech industry. We apply a lot more understanding of the nuances of the industry and have designed truly investable, broad indexes. Q : I am currently long on ALPS Medical Breakthroughs ETF. Convince me to switch to BBC. PY : I think anyone who’s invested in any other biotech fund has probably had a very good experience because the biotech industry has made a lot of technological advances and financial results over the five years. I wouldn’t want to convince anyone to move out of a biotech stock, mutual fund, or competing ETF. But I think it’s important to understand the differences between the investments. Our funds are unique, and it’s important to understand that. Our funds are equally weighted, which means that no company will be an outsized exposure. Biotech is very interesting because you will usually have outsized weighting to an individual drug, regardless of company size. Gilead (NASDAQ: GILD ) showed that to investors about a year ago, last December, when there were pricing concerns that surfaced for its largest drug – Sovaldi and Harvoni for hepatitis C. Within two trading days, Gilead traded down 19%. To have a $150 billion market cap company show that volatility really does show that market cap weighting tends to increase volatility. So, as you can imagine, there are a number of market-weighted biotech ETFs, and they showed higher-than-normal volatility during that period. I think splitting up the risk into the higher-volatility BBC fund and the lower-volatility BBP fund is important because we view them as totally different asset classes: high-risk biotech and low-risk biotech. Some people will want a mix of them; others will want to focus their exposure to these asset classes separately. And because you asked, a third important feature of our fund is that we give people pure biotech exposure. By design, we have excluded special pharmaceuticals, which have been knocked on lately. I think specialty pharma can be good, but some have had political scrutiny these days. It’s important to differentiate these two types of companies because specialty pharma tends to invest 5 to 10% of sales in R&D, whereas biotech companies – even very large ones such as Biogen (NASDAQ: BIIB ) – will invest more than 20% of their sales into R&D. Therefore, specialty pharma companies do not exist in the BBC fund. I think probably every other ETF fund does contain these companies. A lot of other biotech companies have become diluted in what BBC holds because of the emergence of the mega biotech company, such as Biogen or Gilead, as well as the specialty pharma model, such as Horizon, whom we would not classify as a biotech company. Q : Final question: What would you say to an investor who believes the biotech industry is currently a bubble? PY : Well, I think that we have had a 30% or more correction over the past few months and that the long-term growth prospects remain very strong. There are strong arguments that pricing needs to be addressed. I believe these concerns are valid. But some of the scientific approaches are nothing short of remarkable. And valuations have come in significantly. I’m seeing some individual stocks that are making investing in the biotech industry as a whole through ETFs very interesting. Summary Overall, the emphasis Paul Yook expressed in this interview was one of “purity.” While other biotech ETFs diverge out from the biotech industry, investing in big pharma, the BioShares ETFs focus exclusively on biotech. In fact, while BBC currently pales in comparison to most other biotech ETFs in terms of popularity, BioShares holds a second ETF – clearly for the purpose of keeping BBC purely clinical trial based. Hence, the emphasis of “purity” seen for BBC makes this ETF a good investment for an investor who wants biotech and only biotech. That is, if you want explicit exposure to the price gains seen by the creators of up-and-coming drugs, this is your best bet. If you’re looking for something more broad, such as exposure to companies no longer creating drugs but currently in the marketing and sales phase in addition to those up-and-comers, another ETF would be more suitable. Of course, you can gain exposure to both by putting some capital in BBC and some more in BBP or a healthcare ETF. In either case, BBC has a place in the portfolio of investors who believe in the future of biotech breakthroughs.